The CETP inhibitors JTT-705 and torcetrapib have been shown to effectively reduce CETP activity in humans and raise HDL-C, although the effect of this class of compounds on atherosclerosis and CHD risk remains unclear [31,32]. The gene discussed is CETP; the disease is atherosclerosis.